MKManish Khare

Manish Khare

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manish Khare has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Ajay Vikram Singh

    Department of Biotechnology, University of Pune, Ganeshkhind Road, Pune 411 007, India ; Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Room 2145, 110 8th Street, Troy, NY 12180, USA

    1 shared publication
  • Av Singh

    Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, NY 12180, USA ; Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180-3590, USA

    1 shared publication
  • P Zamboni

    Centre for Vascular Disease, University of Ferrara, 41100 Ferrara, Italy

    1 shared publication
  • Paolo Zamboni

    Centre for Vascular Disease, University of Ferrara, 41100 Ferrara, Italy

    1 shared publication
  • W. N. Gade

    Department of Biotechnology, University of Pune, Ganeshkhind Road, Pune 411 007, India

    1 shared publication

Latest Publications

  • Open Access

    Prospect of brain-machine interface in motor disabilities: The future support for multiple sclerosis patient to improve quality of life

    by Av Singh, P Zamboni, M Khare

    Multiple sclerosis (MS) is an autoimmune neurological disorder, which has impacted health related quality of life (HRQoL) more intensively than any other neurological disorder. The approaches to improve the health standard in MS patient are still a subject of primary importance in medical practice and seek a lot of experimental exploration. The present review briefly explains the anomaly in neuron anatomy and dysfunction in signal transmission arising in the context with the chronic cerebrospinal venous insufficiency (CCSVI), a recent hypothesis related with MS pathophysiology. Subsequently, it insights brain-machine interface (BMI) as an alternative approach to improve the HRQoL of MS subjects. Information sources were searched from peer-reviewed data bases (Medline, BioMed Central, PubMed) and grey-literature databases for data published in 2000 or later. We also did systemic search in edited books, articles in seminar papers, reports extracted from newspapers and scientific magazines, articles accessed from internet; mostly using PubMed, Google search engine and Wikipedia. Out of approximately 178, 240 research articles obtained using selected keywords, those articles were included in the present study which addresses the latest definitions of HRQol and latest scientific and ethical developments in the research of MS and BMI. The article presented a brief survey of CCSVI mediated MS and BMI-approach as a treatment to serve the patients suffering from disabilities as a result of MS, followed by successful precedence of BMI approach. Apart from these, the major findings of selected research articles including the development of parameters to define HRQoL, types and development of BMIs and its role in interconnecting brain with actuators, along with CCSVI being a possible cause of MS have formed the foundations to conclude the findings of the present review article. We propose a perspective BMI approach and promises it holds for future research to improve HRQoL in MS patients. In addition, we propose that brain-computer interfaces will be the core of new treatment modalities in the future for MS disabilities.


  • Open Access

    Theranostic Implications of Nanotechnology in Multiple Sclerosis: A Future Perspective

    by Ajay Vikram Singh, Manish Khare, W. N. Gade, Paolo Zamboni

    Multiple Sclerosis is a multifactorial disease with several pathogenic mechanisms and pathways. Successful MS management and medical care requires early accurate diagnosis along with specific treatment protocols based upon multifunctional nanotechnology approach. This paper highlights advances in nanotechnology that have enabled the clinician to target the brain and CNS in patient with multiple sclerosis with nanoparticles having therapeutic and imaging components. The multipartite theranostic (thera(py) + (diag)nostics) approach puts forth strong implications for medical care and cure in MS. The current nanotheranostics utilize tamed drug vehicles and contain cargo, targeting ligands, and imaging labels for delivery to specific tissues, cells, or subcellular components. A brief overview of nonsurgical nanorepair advances as future perspective is also described. Considering the potential inflammatory triggers in MS pathogenesis, a multifunctional nanotechnology approach will be needed for the prognosis.